ABT · Abbott Laboratories

S&P 500 #73 · NYSE

Risiko 4/10 · Solid defensive, post-pullback · $107.27 ▲ 2.66%

Kennzahlen

• Price $107.27
• Market cap $186.8B
• P/E (ttm) 34.72
• Div yield 2.41%
• 52-wk range $81.97 – $137.49
• Index rank #73 / —

Wichtigste Risiken

• CGM market competition (Dexcom, Medtronic) (Investors) — HIGH
• COVID diagnostics revenue normalization drag (Investors) — MED
• Talcum-powder/infant formula litigation tail (Legal/Investors) — LOW
• FDA regulatory risk on new device approvals (Investors) — LOW

Fazit

Diversified medtech and diagnostics leader with strong FreeStyle Libre CGM franchise; stock down ~30% from 2025 highs as COVID tailwinds fade, presenting a revaluation opportunity.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.